Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ALX Oncology Holdings Inc.
  6. Financials
    ALXO   US00166B1052

ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
Real-time Estimate Cboe BZX  -  01:47 2022-08-19 pm EDT
13.93 USD   -3.53%
08/16ALX Oncology's Evorpacept Picked for New Treatment Arm in Breast Cancer Trial
MT
08/16ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer
PR
08/15ALX ONCOLOGY : Corporate Presentation
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 3 435870588--
Enterprise Value (EV)1 3 000507326249241
P/E ratio -31,2x-10,4x-4,95x-4,45x-4,26x
Yield -----
Capitalization / Revenue 2 906x---39,3x
EV / Revenue 2 538x---16,1x
EV / EBITDA -69,0x-6,07x-2,82x-1,71x-1,11x
Price to Book 7,99x2,40x2,28x2,18x3,81x
Nbr of stocks (in thousands) 39 84540 50040 747--
Reference price (USD) 86,221,514,414,414,4
Announcement Date 03/18/202102/28/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 4,801,18---15,0
EBITDA1 --43,5-83,5-116-146-218
Operating profit (EBIT)1 --43,7-83,6-121-154-199
Operating Margin --3 694%----1 328%
Pre-Tax Profit (EBT)1 --45,5-83,5-126-157-193
Net income1 --45,7-83,5-126-158-197
Net margin --3 870%----1 317%
EPS2 -1,15-2,76-2,07-2,92-3,25-3,39
Dividend per Share2 ------
Announcement Date 05/05/202003/18/202102/28/2022---
1 USD in Million
2 USD
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 ------
EBITDA1 ----33,3-34,9-
Operating profit (EBIT)1 -28,5-24,7-33,8-33,5-36,0-37,0
Operating Margin ------
Pre-Tax Profit (EBT)1 -28,5-24,5-32,9-33,4-36,1-37,2
Net income1 -28,4-24,5-32,9-33,5-36,3-37,4
Net margin ------
EPS2 -0,70-0,60-0,81-0,81-0,85-0,86
Dividend per Share ------
Announcement Date 02/28/202205/09/202208/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 -434364262340347
Leverage (Debt / EBITDA) -9,99x4,36x2,26x2,33x1,59x
Free Cash Flow1 --38,3-68,8-91,5-157-201
ROE (Net Profit / Equities) --25,5%-21,1%-36,1%-48,0%-65,0%
Shareholders' equity1 -180396350329303
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 -10,88,946,356,623,79
Cash Flow per Share2 --2,07-1,69-2,52-2,12-2,05
Capex1 -0,030,672,002,705,00
Capex / Sales -2,62%---33,4%
Announcement Date 05/05/202003/18/202102/28/2022---
1 USD in Million
2 USD
Estimates
Key data
Capitalization (USD) 588 387 618
Number of employees 52
Free-Float 73,6%
Free-Float capitalization (USD) 433 196 101
Avg. Exchange 20 sessions (USD) 3 987 042
Average Daily Capital Traded 0,68%
EPS & Dividend